Skip to content

Clinical trials

Phase 1/2 Granulomatous Disease, Chronic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Granulomatous Disease, Chronic Phase: Phase 1/2 Clear all

23 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20042
20061
20071
20081
20112
20134
20141
20151
20171
20181
20222
20243
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated5
Completed5
Enrolling by invitation4
Recruiting3
Unknown status3
Withdrawn2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)7
Genethon2
Children's Hospital Los Angeles1
Children's Hospital of Fudan University1
Ensoma1
Great Ormond Street Hospital for Children NHS Foundation Trust1
Helixmith Co., Ltd.1
Hubert Serve, Prof., MD1
Johann Wolfgang Goethe University Hospital1
Paul Szabolcs1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Granulomatous Disease, Chronic23
Wiskott-Aldrich Syndrome3
Anemia, Sickle Cell2
Common Variable Immunodeficiency2
Inflammatory Bowel Diseases2
Lymphoproliferative Disorders2
Mucopolysaccharidosis I2
Severe Combined Immunodeficiency2
Thalassemia2
Adrenoleukodystrophy1

Trials

Showing 26 to 23 of 23. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.